Account
New to ADSS? Open an
account now to get started.
Already have an account?
Add funds to your ADSS account
Account
New to ADSS? Open an
account now to get started.
Add funds to your ADSS account
News
Thursday, January 22, 2026
What’s happening: Shares of Johnson & Johnson edged lower on Wednesday after the company released its fourth-quarter results.
What happened: The pharmaceutical and medtech giant posted better-than-expected sales and earnings for the quarter.
Although Johnson & Johnson guided to sales crossing $100 billion in 2026, the stock came under pressure due to Trump-related concerns.
How were the results: The New Brunswick, New Jersey-based company reported high single-digit growth in sales for the latest quarter.
Why it matters: Sales in Innovative Medicine, J&J’s largest segment, surged 10% to $15.76 billion, while sales in the Medical Devices unit gained 7.5% to $8.80 billion. Cancer drug sales jumped 24.8% to $6.86 billion, while Immunology sales contracted 8.9% to $3.86 billion. MedTech sales climbed 7.5% to $8.80 billion.
Johnson & Johnson said that its cancer cell therapy Carvykti and Shockwave each recorded annual sales of more than $1 billion.
Johnson & Johnson recently disclosed that it had reached a deal with the US President to lower some prescription drug prices, in exchange for exemptions from Donald Trump’s recently imposed tariffs.
CFO Joseph Wolk indicated that the deal would cost the company “hundreds of millions of dollars.”
Management guided to fiscal 2026 sales of $99.50-$100.5 billion, ahead of market estimates of $98.89 billion. The company also projected adjusted earnings of $11.43-$11.63 per share, broadly in-line with the consensus estimate of $11.45 per share.
How shares responded: Johnson & Johnson’s shares fell 0.1% to close at $218.01 on Wednesday following the release of quarterly earnings. The stock has jumped around 33% over the past six months.
What to watch: Investors will continue monitoring several challenges the company is facing, including tariff concerns in its medical devices division, a lawsuit linking its talc products to ovarian cancer and higher competition for its psoriasis drug Stelara.
Context: The AUD/USD forex pair gained this morning as investors digested the latest jobs data.
Details: Data released this morning showed Australia’s unemployment rate fell to 4.1% in December from 4.3% in November. The figure also came in below market estimates of 4.4%. This signalled the lowest jobless rate since May 2025, with the number of unemployed people declining by 29,800 to a seven-month low of 628,600 in December from 658,400 in the previous month.
Meanwhile, employment rose by 65,200 to a record high of 14.68 million in December. The figure beat market estimates of a 30,000 gain and followed a decline of 28,700 in the previous month.
Strength in the US dollar weighed on the AUD/USD forex pair. The US dollar index, which measures the greenback’s performance versus a basket of major peers, edged higher to 98.78 this morning.
The AUD/USD forex pair rose 0.4% to 0.6787 this morning, while the S&P/ASX 200 climbed 0.73% to trade at 8,846.70.
What to watch: Investors await the release of economic data on S&P Global manufacturing PMI (0200 UAE Time), S&P Global services PMI (0200 UAE Time) and S&P Global composite PMI (0200 UAE Time) from Australia on Friday. Analysts expect the S&P Global Australia manufacturing PMI to decline to 51.3 in January from 51.6 in December, while the services PMI business activity index is expected to rise to 51.5 in January from 51.1 in the previous month.
The S&P Global Australia composite PMI, which declined to 51 in December from 52.6 in the previous month, is expected to rise to 51.3 in January.
Other Markets: US trading indices closed higher on Wednesday, with the Dow Jones index, S&P 500 and Nasdaq 100 up by 1.21%, 1.16% and 1.36%, respectively.
US President Donald Trump said that he is “reasonably close” to an agreement to end the ongoing Russia-Ukraine war. The news sent the USD/RUB pair lower in forex trading this morning.
Japan’s trade surplus declined to ¥105.7 billion in December from ¥120.3 billion in the year-ago month. Exports surging 5.1% year-over-year to a record high of ¥10,411.5 billion exerted pressure on the USD/JPY forex pair.
South Korea’s economy shrank by 0.3% in the fourth quarter, following 1.3% growth in the previous quarter. The latest reading missing market estimates of a 0.1% gain sent the USD/KRW pair higher in forex trading this morning.
New Zealand’s visitor arrivals surged 8.2% year-over-year to 347,600 in November, driven by a surge in arrivals from Australia, which lent support to the NZD/USD forex pair.
Brazil’s Industrial Entrepreneur Confidence Index surged to 48.5 in January from 48.0 in the previous month, sending the USD/BRL pair lower in forex trading this morning.
UK’s CBI distributive trades (1500 UAE Time), Canada’s CFIB business barometer (1600 UAE Time) and new housing price index (1730 UAE Time), Mexico’s mid-month inflation rate (1600 UAE Time), European Central Bank’s monetary policy meeting accounts (1630 UAE Time), as well as US GDP growth rate (1730 UAE Time), initial jobless claims (1730 UAE Time), continuing jobless claims (1730 UAE Time), real consumer spending (1730 UAE Time), PCE price index (1900 UAE Time), personal income (1900 UAE Time), personal spending (1900 UAE Time) and EIA natural gas stockpiles change (1930 UAE Time).
ADSS
8th floor, CI Tower
Corniche Road
PO Box 93894
Abu Dhabi
United Arab Emirates
Trading Services
ts@adss.com
+971 2 657 2414
Investing in CFDs involves a high degree of risk that you will lose your money due to the use of leverage, particularly in fast moving markets, where a relatively small movement in the price can lead to a proportionately larger movement in the value of your investment. This can result in loses that exceed the funds in your account. You should consider whether you understand how CFDs work and you should seek independent advice if necessary.
ADS Securities L.L.C – S.P.C (“ADSS”), a limited liability company – sole proprietorship company incorporated under United Arab Emirates law. Registered under Commercial License No.1190047. ADS Securities L.L.C S.P.C is regulated and authorised in the UAE by the Capital Market Authority (CMA) under Category 1 License No.305027 (Trading Broker, Trading and Clearing Broker, Trading Broker in the International Markets, Trading Broker of OTC Derivatives and Currencies in the Spot Market, Financial Products Dealer) and Category 5 License No.20200000217 (Introduction). Registered Office: 8th Floor, CI Tower, Corniche Road, P.O. Box 93894, Abu Dhabi, United Arab Emirates.
The information presented is not directed at residents of any particular country outside the United Arab Emirates and is not intended for distribution to, or use by, any person in any country where the distribution or use is contrary to local law or regulation.
ADSS is an execution only service provider and does not provide advice. ADSS may publish general market commentary from time to time. Where it does, the material published does not constitute advice, or a solicitation, or a recommendation to a transaction in any financial instrument. ADSS accepts no responsibility for any use of the content presented and any consequences of that use. No representation or warranty is given as to the completeness of this information. Anyone acting on the information provided does so at their own risk.
